Olmesartan medoxomil/ amlodipine/ hydrochlorothiazide: Fixed-dose combination in hypertension

Drugs

Volumn 71, Issue 2, 2011, Pages 209-220

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Amlodipine, pharmacodynamics; Hydrochlorothiazide, pharmacodynamics; Hypertension; Olmesartan medoxomil, pharmacodynamics; Olmesartan medoxomilamlodipinehydrochlorothiazide, general.

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN MEDOXOMIL; AMLODIPINE PLUS OLMESARTAN; ANTACID AGENT; ATORVASTATIN; CIMETIDINE; DIGOXIN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; OLMESARTAN; SILDENAFIL; UNCLASSIFIED DRUG;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; PERIPHERAL EDEMA; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 79551541604     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206770-000000000-00000     Document Type: Article

References (25)

1. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-92
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 - complete version. Hypertension 2003 Dec; 42 (6): 1206-52
3. Safar ME, Struijker-Boudier HAJ. New goals in hyperten- sion management: target-organ protection beyond blood pressure lowering [in French]. Drugs 2003; 63(Special Issue 1): 45-7
4. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27 (11): 2121-58
5. Mancia G, De Backer G, Dominiczak A, et al. 2007 guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-536
6. Wetzels GEC, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004 Oct; 22 (10): 1849-55
7. Daiichi Sankyo Inc. Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets: US prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/200175s000 lbl.pdf [Accessed 2010 Aug 19]
8. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72
9. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov; 50 (5): 896]. Drugs 1995 Sep; 50 (3): 560-86
10. Meredith PA, Elliott HL. Clinical pharmacokinetics of am- lodipine. Clin Pharmacokinet 1992 Jan; 22 (1): 22-31
11. Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006; 66 (14): 1881-901
12. Ferrario C. Effect of angiotensin receptor blockade on en- dothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag 2009; 5 (1): 301-14
13. Armas Padilla MC, Armas-Hernandez MJ, Hernandez RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther 2007 Mar-Apr; 14 (2): 154-60
14. Schwocho LR, Masonson HN. Pharmacokinetics of CS- 866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41 (5): 515-27
15. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988 Nov; 28 (11): 990-4
16. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
17. Oparil S, Melino M, Lee J, et al. Triple therapy with olme- sartan medoxomil, amlodipine besylate, and hydrochloro-thiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010 Jul; 32 (7): 1252-69
18. Izzo J, Melino M, Fernandez V, et al. Twenty-four hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide [abstract no. PO-39]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A34-5
19. Oparil S, Littlejohn T, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) +hydrochlorothiazide (HCTZ) in patients with hypertension and diabetes (the TRINITY study) [abstract no. 670-P]. 70th Annual Scientific Sessions of the American Diabetes Association; 2010 Jun 25-29; Orlando (FL)
20. Chrysant SG, Melino M, Fernandez V, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+ amlodipine besylate (AML) +hydrochlorothiazide (HCTZ) in patients with hypertension: analysis by age and gender [abstract no. PO-30]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A30-1
21. Littlejohn T, Toth P, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besy-late (AML)+hydrochlorothiazide (HCTZ) - the TRINITY study: a subgroup analysis by race [abstract no. PO-50]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A39
22. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped- care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009; 29 (6): 381-91
23. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertension 2009 Sep; 11 (9): 475-82
24. Kereiakes DJ, Sachson RA, Qian C, et al. Efficacy and onset of antihypertensive effects of an amlodipine- and olme-sartan medoxomil-based titration regimen in patients with hypertension and type 2 diabetes [abstract no. PO-233]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A111-2
25. FirstWordSM. Daiichi Sankyo announces first European approval for Sevikar HCT [media release]. 2010 Dec 20